Gaglani M., Kim S.S., Naleway A.L., Levine M.Z., Edwards L., Murthy K., Dunnigan K., Zunie T., Groom H., Ball S., Jeddy Z., Hunt D., Wesley M.G., Sambhara S., Gangappa S., Grant L., Cao W., Liaini Gross F., Mishina M., Fry A.M., Thompson M.G., Dawood F.S., and Flannery B. (2022).

Effect of repeat vaccination on immunogenicity of quadrivalent cell-culture and recombinant influenza vaccines among healthcare personnel aged 18–64 Years: A randomized, open-label trial.

Donenberg G.R., Merrill K.G., Obiezu-Umeh C., Nwaozuru U., Blachman-Demner D., Subramanian S., Fournier A., and Iwelunmor J. (2022).

Harmonizing implementation and outcome data across HIV prevention and care studies in resource-constrained settings.

Chou W.-Y. S., Falisi A.L., Castro K., Ferrer R.A., Gaysynsky A., Huang G.C., Mollica M.A., Peterson E.B., and Kent E.E. (2022).

Cancer clinical trial providers’ perspectives on communicating goals of care: A key informant study.

Porras C., Sampson J.N., Herrero R., Gail M.H., Cortés B., Hildesheim A., Cyr J., Romero B., Schiller J.T., Montero C., Pinto L.A., Schussler J., Coronado K., Sierra M.S., Kim J.J., Torres C.M., Carvajal L., Wagner S., Campos N.G., Ocampo R., Kemp T.J., Zuniga M., Lowy D.R., Avila C., Chanock S., Castrillo A., Estrada Y., Barrientos G., Monge C., Oconitrillo M.Y., and Kreimer A.R. (2022).

Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.

Duarte G., Muresan P., Ward S., Laimon L., Pelton S.I., Canniff J., Golner A., Bone F., Newton L., Fenton T., Coutinho C.M., Joao E.C., Santos B.R., Pilotto J.H., Oliveira R.H., Pinto J.A., Machado E.S., Kreitchman R., Chakhtoura N., Mussi-Pinhata M.M., and Weinberg A. (2022).

Immunogenicity of conjugated and polysaccharide pneumococcal vaccines administered during pregnancy or postpartum to women with HIV.

Bryant K.E., Yuan Y., Engle M., Kurbatova E.V., Allen-Blige C., Batra K., Brown N.E., Chiu K.W., Davis H., Elskamp M., Fagley M., Fedrick P., Hedges K.N.C., Narunsky K., Nassali J., Phan M., Phan H., Purfield A.E., Ricaldi J.N., Robergeau-Hunt K., Whitworth W.C., and Sizemore E.E. (2021).

Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis.

Khan S., Wolin K.Y., Pakpahan R., Grubb R.L., Colditz G.A., Ragard L., Mabie J., Breyer B.N., Andriole G.L., and Sutcliffe S. (2021).

Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.

Frenkel L.M., Morrison R.L., Fuller T.L., Gouvea M.I., Benamor Teixeira M.L., Coombs R.W., Shapiro D.E., Mirochnick M., Hennessey R., Whitson K., Chaktoura N., and Joao E.C. (2021).

Brief report: Vaginal viral shedding with undetectable plasma HIV viral load in pregnant women receiving two different antiretroviral regimens: A randomized clinical trial.

Johnson M.A., Lott C., Qiu C., Galagedera N., Flynn J.M., Cahill P.J., and Anari J.B. (2021).

Rib-based distraction device implantation before age 3 associated with higher unplanned rate of return to the operating room.

Weinberg A., Muresan P., Laimon L., Pelton S.I., Goldblatt D., Canniff J., Zimmer B., Bone F., Newton L., Fenton T., Kiely J., Johnson M.J., Joao E.C., Santos B.R., Machado E.S., Pinto J.A., Chakhtoura N., Duarte G., and Mussi-Pinhata M.M. (2021).

Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: A multicentre randomised controlled trial.

Dawood F.S., Naleway A.L., Flannery B., Levine M.Z., Murthy K., Sambhara S., Gangappa S., Edwards L., Ball S., Grant L., Belongia E., Bounds K., Cao W., Gross F.L., Groom H., Fry A.M., Rentz Hunt D., Jeddy Z., Mishina M., Kim S.S., Wesley M.G., Spencer S., Thompson M.G., and Gaglani M. (2021).

Comparison of the immunogenicity of cell culture-based and recombinant quadrivalent influenza vaccines to conventional egg-based quadrivalent influenza vaccines among healthcare personnel aged 18–64 years: A randomized open-label trial.

Cancelas J.A., Nestheide S., Rugg N., Eckerman A., Macdonald V.W., Charles M.L., Markstrom L., Atkinson A.J., King M.R., Snyder M., Burgess D., Murto J., Valiyaveettil M.K., Pehta J.C., and Penegor S.A. (2021).

Characterization and first-in-human clinical dose-escalation safety evaluation of a next-gen human freeze-dried plasma.

Levy M.E., Waters A., Sen S., Castel A.D., Plankey M., Molock S., Asch F., Goparaju L., and Kassaye S. (2021).

Psychosocial stress and neuroendocrine biomarker concentrations among women living with or without HIV.

Tucker J.D., Iwelunmor J., Abrams E., Donenberg G., Wilson E.C., Blachman-Demner D., Laimon L., Taiwo B.O., Kuhns K.M., John-Stewart G.C., Kohler P., Subramanian S., Ayieko J., Gbaja-Biamila T., Oladele D., Obiezu-Umeh C., Chima K.P., Jalil E.M., Falcao J., Ezechi O.C., and Kapogiannis B.G. (2021).

Accelerating adolescent HIV research in LMICs: The NICHD HIV prevention and treatment through a comprehensive care continuum (PATC3H) consortium.

Monroe A.K., Levy M.E., Greenberg A.E., Keruly J.C., Moore R.D., Horberg M.A., Kulie P., Mohanraj B.S., Kumar P.N., and Castel A.D. (2021).

Integrase inhibitor prescribing disparities in the DC and Johns Hopkins HIV cohorts.

Koay W.L.A., Dirajlal-Fargo S., Levy M.E., Kulie P., Monroe A., Castel A.D., and Rakhmanina N.Y. (2021).

Integrase strand transfer inhibitors and weight gain in children and youth with perinatal human immunodeficiency virus in the DC cohort.

Aschengrau A., Mussi-Pinhata M.M., Moye J., Chakhtoura N., Patel K., Williams P.L., Karalius B., Garvie P.A., Monte D., Whalen F., Lebov J., and Seage G.R. (2021).

An international prospective cohort study of HIV and Zika in infants and pregnancy (HIV ZIP): Study protocol.

Golmard L., Vasta L.M., Duflos V., Corsini C., d'Enghien C.D., McMaster M.L., Harney L.A., Carr A.G., Ling A., Dijoud F., Gauthier A., Miettinen M., Cost N.G., Gauthier-Villars M., Orbach D., Irtan S., Haouy S., Schultz K.A., Stoppa-Lyonnet D., Coupier I., Stewart D.R., and Sirvent N. (2021).

Testicular Sertoli cell tumour and potentially testicular Leydig cell tumour are features of DICER1 syndrome.

Mirshahi U.L., Kim J., Best A.F., Chen Z.E., Hu Y., Haley J.S., Golden A., Stahl R., Manickam K., Carr A.G., Harney L.A., Field A., Hatton J., Schultz K.A.P., Bauer A.J., Hill D.A., Rosenberg P.S., Murray M.F., Carey D.J., and Stewart D.R. (2021).

A genome-first approach to characterize DICER1 pathogenic variant prevalence, penetrance, and phenotype.

Vasta L.M., Khan N.E., Higgs C.P., Harney L.A., Carr A.G., Harris A.K., Schultz K.A.P., McMaster M.L., and Stewart D.R. (2021).

Hematologic indices in individuals with pathogenic germline DICER1 variants.

Vasta L.M., McMaster M.L., Harney L.A., Ling A., Kim J., Harris A.K., Carr A.G., Damrauer S.M., Rader D.J., Kember R.L., Kanetsky P.A., Nathanson K.L., Pyle L.C., Greene M.H., Schultz K.A., and Stewart D.R. (2020).

Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors.

Merideth M.A., Harney L.A., Vyas N., Bachi A., Carr A.G., Hill D.A., Dehner L.P., Schultz K.A., Stewart D.R., and Stratton P. (2020).

Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.

Anderson C., Nichols H., House M., and Sandler D.P. (2019).

Risk versus benefit of chemoprevention among raloxifene and tamoxifen users with a family history of breast cancer.

Havens P.L., Perumean-Chaney S.E., Patki A., Cofield S.S., Wilson C.M., Liu N., Anderson P.L., Landovitz R.J., Kapogiannis B.G., Hosek S.G., and Mulligan K. (2019).

Changes in bone mass after discontinuation of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine in young men who have sex with men: Extension phase results of Adolescent Trials Network Protocols 110 and 113.

Havens P.L., Tamhane A., Stephensen C.B., Schuster G.U., Gordon C.M., Liu N., Wilson C.M., Hosek S.G., Anderson P.L., Kapogiannis B.G., and Mulligan K. (2019).

Short communication: Association of vitamin D Insufficiency and protective tenofovir diphosphate concentrations with bone toxicity in adolescent boys and young men using tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis.

Mitchell R., Brown R., Fulton J., Alexander M., and Black S. (2019).

Do-it-yourself CDISC! A case study of Westat's successful implementation of CDISC standards on a fixed budget.

Lipman P.D., Dluzak L., and Stoney C.M. (2019).

Is this study feasible? Facilitating management of pragmatic trial planning milestones under a phased award funding mechanism.

Rohan E.A., Slotman B., Goettsche Tristani E., Townsend J.S., White D.E., Fultz-Butts K., and Gardner A. (2019).

Evaluating the feasibility of using a mobile app to track oncology patient navigation activities and outcomes.

Yeganeh N., Kerin T., Ank B., Watts D.H., Camarca M., Joao E.C., Pilotto J.H., Veloso V.G., Bryson Y., Gray G., Theron G., Dickover R., Morgado M.G., Santos B., Kreitchmann R., Mofenson L., and Nielsen-Saines K. (2018).

Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study.

Havens P.L., Stephensen C.B., Van Loan M.D., Schuster G.U., Woodhouse L.R., Flynn P.M., Gordon C.M., Pan C.G., Rutledge B., Harris D.R., Price G., Baker A., Meyer W.A., Wilson C.M., Hazra R., Kapogiannis B.G., Mulligan K., and Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team (2018).

Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency virus infection being treated with tenofovir disoproxil fumarate: A randomized, placebo-controlled trial.

Havens P.L., Tamhane A., Stephensen C.B., Schuster G.U., Gordon C.M., Liu N., Wilson C.M., Hosek S.G., Anderson P.L., Kapogiannis B.G., and Mulligan K. (2018).

Association of vitamin D insufficiency and protective tenofovir diphosphate concentrations with bone toxicity in adolescent boys and young men using tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis.

Chung D.C., McCague S., Yu Z.F., Thill S., DiStefano-Pappas J., Bennett J., Cross D., Marshall K., Wellman J., and High K.A. (2018).

Novel mobility test to assess functional vision in patients with inherited retinal dystrophies.

Mollica M.A., Kent E.E., Castro K.M., Ellis E.M., Ferrer R.A., Falisi A.L., Gaysynsky A., Huang G., Palan M.A., and Chou W.S. (2018).

Perspectives on palliative care in cancer clinical trials: Diverse meanings from multidisciplinary cancer care providers.

Kapogiannis B.G., Wilson C.M., Price G.N., Harris D.R., Hazra R., Mulligan K., Havens P.L., Stephensen C.B., Flynn P.M., Rutledge B., Pan C.G., Woodhouse L.R., Van Loan M.D., Baker A., Gordon C.M., Shuster G.U., and Meyer W.A. (2018).

Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with HIV infection being treated with tenofovir disoproxil fumarate: A randomized, placebo-controlled trial.

Mast A.E., Bialkowski W., Bryant B.J., Wright D.J., Birch R.J., Kiss J.E., D'Andrea P., Cable R.G., and Spencer B.R. (2016).

A randomized, blinded, placebo-controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors.

Gohagan J.K., Prorok P.C., Yurgalevitch S., Miller A.B., Feld R., Fontana R., Jatoi I., Lawrence W., Miller A., Rajput A., Sherman M., Welch G., Wright P., and Albertsen P. (2015).

Changes in and impact of the death review process in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Want to work with us?
You’ll be in great company.

About Us Careers

Westat Employees.
Westat Employee.
AAA Foundation for Traffic Safety
Baltimore Metropolitan Council
Centers for Disease Control and Prevention
Centers for Medicare & Medicaid Services
Chicago Metropolitan Agency for Planning
DC Public Schools
Georgia Department of Transportation
Internal Revenue Service
Leadership Montgomery
Maryland Cancer Registry
Michigan Department of Health and Human Services
National Science Foundation
NYC Mayor’s Office for Economic Opportunity
Organization for Economic Cooperation and Development
Robert Wood Johnson Foundation
Social Security Administration
Substance Abuse and Mental Health Services Administration
Teach for America
Texas Education Agency
The Johns Hopkins University
The National Institutes of Health
The Verizon Foundation
U.S. Department of Agriculture
U.S. Department of Education
U.S. Department of Health and Human Services
U.S. Department of Justice
U.S. Department of Transportation
U.S. Department of Veterans Affairs
University of Maryland Baltimore Campus
University of Michigan
University System of Maryland
Explore Our Clients

Please wait...

Forbes 2022 The Best Employers for Women Powered by Statista

Westat is an Equal Opportunity Employer and does not discriminate on the basis of race, creed, color, religion, sex, national origin, age, veteran status, disability, marital status, sexual orientation, citizenship status, genetic information, gender identity or expression, or any other protected status under applicable law. Notices to Employees & Applicants.